title: Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82.
authors.forename: Michael
authors.initials: M
authors.lastname: Lauseker
authors.forename: Markus
authors.initials: M
authors.lastname: Pfirrmann
authors.forename: Verena S
authors.initials: VS
authors.lastname: Hoffmann
authors.forename: Joerg
authors.initials: J
authors.lastname: Hasford
mesh_terms: D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*
chemical_list: D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines